deltatrials
Completed PHASE3 NCT00002534

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Leukemia
Interventions allogeneic bone marrow transplantation anti-thymocyte globulin cyclophosphamide cytarabine in vitro-treated bone marrow transplantation low-LET electron therapy low-LET photon therapy methylprednisolone thiotepa
Updated 5 times since 2017 Last updated: Jun 24, 2013 Started: May 31, 1993 Primary completion: Apr 30, 2003 Completion: Apr 30, 2003

Listed as NCT00002534, this PHASE3 trial focuses on Leukemia and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 1993, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

May 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States